Muscarinic acetylcholine receptor
8 drugs CNS
3
approved indications
8
Approved Drugs
8
Companies
14
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 8 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (14 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EXELA PHARMA 1 drug
Novartis 1 drug
AZURITY 1 drug
By Therapeutic Area
Other 7 drugs
CNS 1 drugs
Drugs by Company PRO
EXELA PHARMA 1 drug
Novartis 1 drug
AZURITY 1 drug
AbbVie 1 drug
MMT 1 drug
NOVEL LABS INC 1 drug
Bristol-Myers Squibb 1 drug
GENUS 1 drug
By Therapeutic Area
Other 7 drugs
GLYRX-PF, ISOPTO ATROPINE, PREVDUO, OXYTROL +3 more
CNS 1 drugs
COBENFY
Indications Treated
CoughNeuromuscular BlockadeBradycardiaSchizophreniaOveractive BladderUrge Urinary IncontinenceAnesthesiaArrhythmiasPeptic UlcerMydriasisCycloplegiaAmblyopiaOrganophosphorus Nerve Agent PoisoningOrganophosphorus Insecticide Poisoning
All Drugs Targeting Muscarinic acetylcholine receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| GLYRX-PF | EXELA PHARMA | 2018 | 3 | |
| ISOPTO ATROPINE | Novartis | 2016 | 3 | |
| PREVDUO | AZURITY | 2023 | 2 | |
| OXYTROL | AbbVie | 2003 | 2 | |
| DUODOTE | MMT | 2006 | 2 | |
| HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | NOVEL LABS INC | 1983 | 1 | |
| COBENFY | Bristol-Myers Squibb | 2024 | 1 | CNS |
| HYCODAN | GENUS | 1943 | 1 |